Added to YB: 2025-07-25
Pitch date: 2025-07-22
NOVO-B.CO [bullish]
Novo Nordisk A/S
-24.44%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 425.03
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
GUYQUITY 2025 Q2 Portfolio new position - Novo Nordisk A/S
NOVO-B.CO (new position): Ozempic/Wegovy leader dominating GLP-1 market for diabetes/obesity. Recent drop from high valuation, supply issues & US pricing fears, but long-term demand remains strong. Unlike typical biopharma, Novo has cash generation, ex-US pricing power, dividends & organic growth without M&A dependency.
Read full article (1 min)